259 related articles for article (PubMed ID: 10479120)
1. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant.
Pass RF; Duliegè AM; Boppana S; Sekulovich R; Percell S; Britt W; Burke RL
J Infect Dis; 1999 Oct; 180(4):970-5. PubMed ID: 10479120
[TBL] [Abstract][Full Text] [Related]
2. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine.
Frey SE; Harrison C; Pass RF; Yang E; Boken D; Sekulovich RE; Percell S; Izu AE; Hirabayashi S; Burke RL; Duliège AM
J Infect Dis; 1999 Nov; 180(5):1700-3. PubMed ID: 10515836
[TBL] [Abstract][Full Text] [Related]
3. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
[TBL] [Abstract][Full Text] [Related]
4. A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
Adler SP; Plotkin SA; Gonczol E; Cadoz M; Meric C; Wang JB; Dellamonica P; Best AM; Zahradnik J; Pincus S; Berencsi K; Cox WI; Gyulai Z
J Infect Dis; 1999 Sep; 180(3):843-6. PubMed ID: 10438376
[TBL] [Abstract][Full Text] [Related]
5. Detection of cytomegalovirus infection during a vaccine clinical trial in healthy young women: seroconversion and viral shedding.
Zhang C; Buchanan H; Andrews W; Evans A; Pass RF
J Clin Virol; 2006 Mar; 35(3):338-42. PubMed ID: 16388984
[TBL] [Abstract][Full Text] [Related]
6. Vaccination of seropositive subjects with CHIRON CMV gB subunit vaccine combined with MF59 adjuvant for production of CMV immune globulin.
Drulak MW; Malinoski FJ; Fuller SA; Stewart SS; Hoskin S; Duliege AM; Sekulovich R; Burke R; Winston S
Viral Immunol; 2000; 13(1):49-56. PubMed ID: 10733168
[TBL] [Abstract][Full Text] [Related]
7. Detection of cytomegalovirus infection during clinical trials of glycoprotein B vaccine.
Zhang C; Pass RF
Vaccine; 2004 Dec; 23(4):507-10. PubMed ID: 15530699
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
[TBL] [Abstract][Full Text] [Related]
9. Avidity maturation following immunization with two human cytomegalovirus (CMV) vaccines: a live attenuated vaccine (Towne) and a recombinant glycoprotein vaccine (gB/MF59).
Marshall BC; Adler SP
Viral Immunol; 2003; 16(4):491-500. PubMed ID: 14733736
[TBL] [Abstract][Full Text] [Related]
10. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection.
Schleiss MR; Bourne N; Bernstein DI
J Infect Dis; 2003 Dec; 188(12):1868-74. PubMed ID: 14673766
[TBL] [Abstract][Full Text] [Related]
11. Location, location, timing: analysis of cytomegalovirus epitopes for neutralizing antibodies.
Schrader JW; McLean GR
Immunol Lett; 2007 Sep; 112(1):58-60. PubMed ID: 17714794
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12.
Jacobson MA; Sinclair E; Bredt B; Agrillo L; Black D; Epling CL; Carvidi A; Ho T; Bains R; Girling V; Adler SP
Vaccine; 2006 Jun; 24(25):5311-9. PubMed ID: 16701925
[TBL] [Abstract][Full Text] [Related]
13. Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation.
Baraniak I; Gomes AC; Sodi I; Langstone T; Rothwell E; Atkinson C; Pichon S; Piras-Douce F; Griffiths PD; Reeves MB
EBioMedicine; 2019 Dec; 50():45-54. PubMed ID: 31735553
[TBL] [Abstract][Full Text] [Related]
14. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
Lilja AE; Mason PW
Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.
Bernstein DI; Reap EA; Katen K; Watson A; Smith K; Norberg P; Olmsted RA; Hoeper A; Morris J; Negri S; Maughan MF; Chulay JD
Vaccine; 2009 Dec; 28(2):484-93. PubMed ID: 19857446
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines.
Heineman TC; Schleiss M; Bernstein DI; Spaete RR; Yan L; Duke G; Prichard M; Wang Z; Yan Q; Sharp MA; Klein N; Arvin AM; Kemble G
J Infect Dis; 2006 May; 193(10):1350-60. PubMed ID: 16619181
[TBL] [Abstract][Full Text] [Related]
17. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine.
Schleiss MR; Bourne N; Stroup G; Bravo FJ; Jensen NJ; Bernstein DI
J Infect Dis; 2004 Apr; 189(8):1374-81. PubMed ID: 15073673
[TBL] [Abstract][Full Text] [Related]
18. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
[TBL] [Abstract][Full Text] [Related]
19. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
[TBL] [Abstract][Full Text] [Related]
20. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]